canertinib has been researched along with n-phenylacrylamide in 1 studies
| Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (n-phenylacrylamide) | Trials (n-phenylacrylamide) | Recent Studies (post-2010) (n-phenylacrylamide) |
|---|---|---|---|---|---|
| 124 | 9 | 65 | 19 | 0 | 19 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderton, MJ; Ashton, S; Bethel, PA; Box, M; Butterworth, S; Chorley, CG; Chuaqui, C; Colclough, N; Cross, DA; Dakin, LA; Debreczeni, JÉ; Eberlein, C; Finlay, MR; Grist, M; Hill, GB; Klinowska, TC; Lane, C; Martin, S; Orme, JP; Smith, P; Wang, F; Ward, RA; Waring, MJ | 1 |
1 other study(ies) available for canertinib and n-phenylacrylamide
| Article | Year |
|---|---|
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
Topics: ErbB Receptors; Models, Molecular; Mutation; Structure-Activity Relationship | 2013 |